ArticleDermatology and therapy2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis).
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world evidence on deucravacitinib in moderate-to-severe psoriasis remains limited, especially regarding difficult-to-treat areas such as scalp involvement. We conducted a multicenter retrospective study to assess the short-term effectiveness and safety of deucravacitinib in routine clinical practice, with a specific focus on scalp outcomes.
methodsWe enrolled 111 adult patients with moderate-to-severe psoriasis treated with deucravacitinib for at least 16 weeks across 19 different Italian dermatology units. Effectiveness was assessed in terms of PASI (Psoriasis Area and Severity Index) responses and scalp-specific Physician's Global Assessment (ss-PGA).
resultsAt week 16, PASI 75, PASI 90, and PASI 100 were achieved by 49.6%, 29.7%, and 18.9% of patients, respectively, with response rates further improving to 84.9%, 60.6%, and 45.5% at week 32. Among patients with baseline scalp involvement (n = 49), 89.8% reached ss-PGA 0/1 at week 16 and 100% at week 32, showing rapid and sustained scalp clearance. Notably, baseline scalp involvement did not negatively affect overall skin response. Deucravacitinib demonstrated a favorable safety profile. Adverse events (AEs) were reported by 8.1% of patients and were all mild in severity. Treatment was discontinued in 2.7% of patients, and no severe AEs were observed.
conclusionDeucravacitinib demonstrated clinical effectiveness and a favorable safety profile in real-world practice, including excellent scalp clearance rates, confirming its therapeutic value even in patients with difficult-to-treat areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.